Cancer Research and Treatment

Woo Chan Park

2 Articles

Clinical Features of Male Breast Cancer: Experiences from Seven Institutions Over 20 Years: Ji Hyung Hong, Kyung Sun Ha, Yun Hwa Jung, Hye Sung Won, Ho Jung An, Guk Jin Lee, Donghoon Kang, Ji Chan Park, Sarah Park, Jae Ho Byun, Young Jin Suh, Jeong Soo Kim, Woo Chan Park, Sang Seol Jung, Il Young Park, Su-Mi Chung, In Sook Woo; Cancer Res Treat. 2016;48(4):1389-1398. Published online April 11, 2016; DOI: https://doi.org/10.4143/crt.2015.410

Purpose
Breast cancer treatment has progressed significantly over the past 20 years. However, knowledge regarding male breast cancer (MBC) is sparse because of its rarity. This study is an investigation of the clinicopathologic features, treatments, and clinical outcomes of MBC.
Materials and Methods
Clinical records of 59 MBC patients diagnosed during 1995-2014 from seven institutions in Korea were reviewed retrospectively.
Results
Over a 20-year period, MBC patients accounted for 0.98% among total breast cancer patients, and increased every 5 years. The median age of MBC patientswas 66 years (range, 24 to 87 years). Forty-three patients (73%) complained of a palpable breast mass initially. The median symptom duration was 5 months (range, 1 to 36 months). Mastectomy was performed in 96% of the patients. The most frequent histology was infiltrating ductal carcinoma (75%). Ninety-one percent of tumors (38/43) were estrogen receptor–positive, and 28% (11/40) showed epidermal growth factor receptor 2 (HER-2) overexpression. After curative surgery, 42% of patients (19/45) received adjuvant chemotherapy; 77% (27/35) received hormone therapy. Five out of ten patients with HER-2 overexpressing tumors did not receive adjuvant anti–HER-2 therapy, while two out of four patients with HER-2 overexpressing tumors received palliative trastuzumab for recurrent and metastatic disease. Letrozole was used for one patient in the palliative setting. The median overall survival durations were 7.2 years (range, 0.6 to 17.0 years) in patients with localized disease and 2.9 years (range, 0.6 to 4.3 years) in those with recurrent or metastatic disease.
Conclusion
Anti–HER-2 and hormonal therapy, except tamoxifen, have been underutilized in Korean MBC patients compared to female breast cancer patients. With the development of precision medicine, active treatment with targeted agents should be applied. Further investigation of the unique pathobiology of MBC is clinically warranted.

Citations

Citations to this article as recorded by

Cost-effectiveness of adjuvant endocrine treatment with tamoxifen for male breast cancer
Yaping Huang, Chengjie Ke, Jiaqin Cai, Xiaoxia Wei, Maohua Chen, Hong Sun
Breast Cancer.2024; 31(5): 917. CrossRef
Cáncer de mama en el varón: estudio multicéntrico en Aragón durante 27 años
Olga Dobato Portoles, Daniel Aparicio Lopez, Reyes Ibañez Carreras, Elena Aguirre Ortega, Beatriz Eizaguirre Zarza, Carmen García Mur, Aurora Carrasquer Puyal, María Pilar Cebollero Benito, Laura Isabel Comín Novella, Marta Allue Cabañuz, Fernando Martine
Cirugía Española.2024; 102(10): 524. CrossRef
Observational Study of Men and Women with Breast Cancer in Terms of Overall Survival
Vlad Bogdan Varzaru, Diana-Maria Anastasiu-Popov, Anca-Elena Eftenoiu, Roxana Popescu, Daliborca Cristina Vlad, Cristian Sebastian Vlad, Aurica Elisabeta Moatar, Daniela Puscasiu, Ionut Marcel Cobec
Cancers.2024; 16(17): 3049. CrossRef
Male breast cancer: A multicenter study in Aragon over 27 years
Olga Dobato Portoles, Daniel Aparicio Lopez, Reyes Ibañez Carreras, Elena Aguirre Ortega, Beatriz Eizaguirre Zarza, Carmen García Mur, Aurora Carrasquer Puyal, María Pilar Cebollero Benito, Laura Isabel Comín Novella, Marta Allue Cabañuz, Fernando Martine
Cirugía Española (English Edition).2024; 102(10): 524. CrossRef
Male breast cancer: a 32-year retrospective analysis in radiation therapy referral center in northern Iran
Mahboobeh Asgharian, Dariush Moslemi, Hossein-Ali Nikbakht, Mohammad-Ali Jahani, Ali Bijani, Hakimeh Mehdizadeh
Annals of Medicine & Surgery.2024; 86(10): 5756. CrossRef
Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09)
Jieun Lee, Keun Seok Lee, Sung Hoon Sim, Heejung Chae, Joohyuk Sohn, Gun Min Kim, Kyung-Hee Lee, Su Hwan Kang, Kyung Hae Jung, Jae-ho Jeong, Jae Ho Byun, Su-Jin Koh, Kyoung Eun Lee, Seungtaek Lim, Hee Jun Kim, Hye Sung Won, Hyung Soon Park, Guk Jin Lee, S
Cancer Research and Treatment.2023; 55(1): 123. CrossRef
Clinicopathological features and correlation analysis of male breast cancer
Lei Xi, Jinxing Zhou, Yan Wu, Rong Rong
Medicine.2023; 102(30): e34408. CrossRef
Characteristics of metastasis and survival between male and female breast cancer with different molecular subtypes: A population‐based observational study
Wentong Fang, Yue Huang, Xu Han, Jinghui Peng, Mingjie Zheng
Cancer Medicine.2022; 11(3): 764. CrossRef
Comparison of short-term surgical outcomes between men and women with breast cancer: a retrospective study using nationwide inpatient data in Japan
Takaaki Konishi, Michimasa Fujiogi, Nobuaki Michihata, Kojiro Morita, Hiroki Matsui, Kiyohide Fushimi, Masahiko Tanabe, Yasuyuki Seto, Hideo Yasunaga
Breast Cancer Research and Treatment.2021; 186(3): 731. CrossRef
Ulcerated Nipple Nodule, Clinicopathologic Challenge: Answer
Ahmad Adel, Mona R. E. Abdel-Halim, Yosra Abdel-Galeil
The American Journal of Dermatopathology.2021; 43(6): 466. CrossRef
Genetic Landscape of Male Breast Cancer
Fernando Augusto Batista Campos, Etienne Rouleau, Giovana Tardin Torrezan, Dirce Maria Carraro, José Claudio Casali da Rocha, Higor Kassouf Mantovani, Leonardo Roberto da Silva, Cynthia Aparecida Bueno de Toledo Osório, Solange Moraes Sanches, Sandrine M.
Cancers.2021; 13(14): 3535. CrossRef
Treatment of male breast cancer: meta-analysis of real-world evidence
A. P. Lin, T.-W. Huang, K.-W. Tam
British Journal of Surgery.2021; 108(9): 1034. CrossRef
Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells
Ana D. Pinzón-García, Ruben Sinisterra, Maria Cortes, Fredy Mesa, Sandra Ramírez-Clavijo
PeerJ.2021; 9: e12124. CrossRef
Prognostic Factors in Male Breast Cancer: A Retrospective Nationwide Study in South Korea by the Study of SMARTSHIP Group
Sungmin Park, Ho Hur, Ji Sung Lee, JaeSun Yoon, Sung Mo Hur, Il Yong Chung, Jong Won Lee, Hyun Jo Youn, Se Jeong Oh, Cheol Wan Lim, Jihyoun Lee
Journal of Breast Cancer.2021; 24(6): 561. CrossRef
Meme Kanseri Cerrahisi Sonrası Lenfödem ve Uçak Seyahati
Aysel GÜL, Dilek AYGİN
İstanbul Gelişim Üniversitesi Sağlık Bilimleri Dergisi.2021; (15): 669. CrossRef
Italian Men Tested for BRCA1/2 Mutation: Psychological Distress during 6-Month Follow-Up
F. Pellini, S. Mirandola, E. Granuzzo, S. Urbani, G. Piccinni Leopardi, G. P. Pollini
Journal of Oncology.2020; 2020: 1. CrossRef
Comparing the Characteristics and Outcomes of Male and Female Breast Cancer Patients in Korea: Korea Central Cancer Registry
Eun-Gyeong Lee, So-Youn Jung, Myong Cheol Lim, Jiwon Lim, Han-Sung Kang, Seeyoun Lee, Jai Hong Han, Heein Jo, Young-Joo Won, Eun Sook Lee
Cancer Research and Treatment.2020; 52(3): 739. CrossRef
The effect of chemotherapy on survival in patients with nonmetastatic male breast cancer: A population‐based observational study
Hong Pan, Kai Zhang, Ming Wang, Lijun Ling, Shui Wang, Wenbin Zhou
Cancer.2020; 126(S16): 3830. CrossRef
Adjuvant Radiation Therapy for Male Breast Cancer—A Rare Indication?
Tobias Forster, Clara Köhler, Rami El Shafie, Fabian Weykamp, Laila König, Nathalie Arians, Sebastian Adeberg, Laura Michel, Katharina Smetanay, Michael Golatta, Christof Sohn, Jörg Heil, Andreas Schneeweiss, Jürgen Debus, Juliane Hörner-Rieber
Cancers.2020; 12(12): 3645. CrossRef
Male Breast Cancer: Surgical and Genetic Features and a Multidisciplinary Management Strategy
Francesca Pellini, Eleonora Granuzzo, Silvia Urbani, Sara Mirandola, Marina Caldana, Davide Lombardi, Elena Fiorio, Marta Mandarà, Giovanni Paolo Pollini
Breast Care.2020; 15(1): 14. CrossRef
Ultrasonographic and Mammographic Findings of Male Breast Disease
Su Hong Kim, Young‐Seon Kim
Journal of Ultrasound in Medicine.2019; 38(1): 243. CrossRef
Pattern of care of adjuvant radiotherapy in male breast cancer patients in clinical practice: an observational study
Paul Rogowski, Stephan Schönecker, Montserrat Pazos, Daniel Reitz, Michael Braun, Martin Pölcher, Claus Hanusch, Rachel Wuerstlein, Nadia Harbeck, Sven Mahner, Claus Belka, Stefanie Corradini
Strahlentherapie und Onkologie.2019; 195(4): 289. CrossRef
Survival analysis for male ductal and lobular breast cancer patients with different stages
Jizhao Wang, Yuchen Sun, Jingkun Qu, Huang Zuo, Xixi Zhao, Lin Liu, Jinteng Feng, Jiansheng Wang, Guangjian Zhang
Future Oncology.2019; 15(2): 167. CrossRef
Clinical features of patients with male breast cancer in Shanxi province of China from 2007 to 2016
Weigang Wang, Xiaoqin Xu, Baoguo Tian, Yan Wang, Lili Du, Ting Sun, Yanchun Shi, Xianwen Zhao, Yali Jia, Yanfeng Xi, Jiexian Jing
Journal of Investigative Medicine.2019; 67(3): 699. CrossRef
Metastasis pattern and prognosis of male breast cancer patients in US: a population-based study from SEER database
Jun Xie, Yao-Yu Ying, Bin Xu, Yan Li, Xian Zhang, Chong Li
Therapeutic Advances in Medical Oncology.2019;[Epub] CrossRef
Different Patterns of Conditional Survival of Breast Cancer Patients by Age and Histologic Types: Evidence from the Korean Nationwide Registry
So-Youn Jung, Kyu-Won Jung, Johyun Ha, Young-Joo Won, Young Ae Kim, Youngmee Kwon, Sun-Young Kong, Eun Sook Lee
Cancer Epidemiology, Biomarkers & Prevention.2019; 28(7): 1169. CrossRef
Diagnostic Value of Fine-Needle Aspiration in Male Breast Lesions
Raza S. Hoda, Ronald N. Arpin III, Ravi V. Gottumukkala, Kevin S. Hughes, Amy Ly, Elena F. Brachtel
Acta Cytologica.2019; 63(4): 319. CrossRef
The endocrinology of male breast cancer
Ian S Fentiman
Endocrine-Related Cancer.2018; 25(6): R365. CrossRef
Magee Equation Recurrence Score Is Associated With Distal Metastatic Risk in Male Breast Carcinomas
Yanjun Hou, Harrison S Moosavi, Lai Wei, Anil V Parwani, Xiaoxian (Bill) Li, Zaibo Li
American Journal of Clinical Pathology.2018; 150(6): 491. CrossRef
Axillary lymph node metastasis as the first manifestation of male occult breast cancer
Xinyu Wang, Liwen Fan, Wenxing Yan, Qi Zhang, Shunchao Bao, Ying Wang, Xin Bao, Linlin Liu
Medicine.2018; 97(50): e13706. CrossRef
A review of estrogen receptor/androgen receptor genomics in male breast cancer
Tesa M Severson, Wilbert Zwart
Endocrine-Related Cancer.2017; 24(3): R27. CrossRef
Imaging the Male Breast
Shruthi Ram, Shadi Aminololama-Shakeri
Current Radiology Reports.2017;[Epub] CrossRef
Mammary gland tumors in a male Cocker Spaniel
Soon-Chan Kwon, Dae-Young Yoo, Minho Ko, Kwon-Young Lee, Ho-Hyun Kwak, In-Chul Park, In-Koo Hwang, Jung-Hoon Choi, Jin-Young Chung
Acta Veterinaria Scandinavica.2017;[Epub] CrossRef
Male occult breast cancer with axillary lymph node metastasis as the first manifestation
Ruixin Xu, Jianbin Li, Yingjie Zhang, Hongbiao Jing, Youzhe Zhu
Medicine.2017; 96(51): e9312. CrossRef

14,025 View
246 Download
36 Web of Science
34 Crossref

A Clinical Analysis of PTEN Expressions in Breast Cancers: Hang Ju Cho, Jeong Soo Kim, Kee Hwan Kim, Chang Hyeok Ahn, Woo Chan Park, Se Jeong Oh, Sang Seol Jung, Keun Woo Lim, Seock Ah Im; Cancer Res Treat. 2003;35(2):102-108. Published online April 30, 2003; DOI: https://doi.org/10.4143/crt.2003.35.2.102

Abstract PDF

PURPOSE
The PTEN gene, a novel tumor suppressor, is localized to chromosome 10q23.3 and shares extensive homology with the cytoskeletal protein, tensin. A high frequency of mutations at the PTEN locus has been described in a variety of neoplasms including breast cancer and Cowden Disease. However, the role of PTEN alterations and its association with clinicopathological factors have not been well established. We investigated the relationship between the PTEN expression and clinicopathological factors.
MATERIALS AND METHODS
Formalin-fixed, paraffin-embedded tissues from 105 women with breast cancer were evaluated for the PTEN expression and were scored semi-quantitatively based on staining intensity and distribution. Results were statistically compared with clinicopathological factors.
RESULTS
Forty-seven (45%) of the 105 breast cancers had a loss of the PTEN expression. In the recurrent group, 19 of 32 (59%) patients showed a loss of the PTEN expression, whereas in the non-recurrent group, only 28 of 73 (38%) patients showed a loss of the PTEN expression. The loss of PTEN expression correlated with estrogen receptors (ER) (p=0.027), recurrence (p=0.046), HER-2/neu overexpression (p=0.016), disease-free survival (p=0.0163), and overall survival (p=0.0357). In particular, when HER-2/ neu was overexpressed, the overall survival rate correlated with the loss of PTEN expression statistically (p=0.0454), whereas when HER-2/neu was negative, there was no correlation (p=0.9808). Progesterone receptor (PR) and disease stage had no relationship with the PTEN expression. CONCLUSION: Our results support that PTEN plays a role as a tumor suppressor in breast cancer and is a prognostic factor in predicting recurrence.

Citations

Citations to this article as recorded by

The prognostic value and potential drug target of phosphatase and tensin homolog in breast cancer patients
Feng Xu, Chao Zhang, Jianxiu Cui, Jun Liu, Jie Li, Hongchuan Jiang
Medicine.2017; 96(36): e8000. CrossRef

3,643 View
32 Download
1 Crossref

Author index